Search clinical trials for: Bardoxolone Methyl: 20 mg

Total 978 results

Reata, a wholly owned subsidiary of Biogen

Withdrawn

A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis

Type 2 Diabetes Mellitus | End-Stage Renal Disease
Biogen

Terminated

A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes

Type 2 Diabetes | Chronic Kidney Disease
Reata, a wholly owned subsidiary of Biogen

Terminated

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON)

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
Reata, a wholly owned subsidiary of Biogen

Completed

A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl

Healthy Volunteers

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects

Healthy

United States
Reata, a wholly owned subsidiary of Biogen

Withdrawn

Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
Reata, a wholly owned subsidiary of Biogen

Completed

Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

Healthy | Hepatic Impairment

United States
Reata, a wholly owned subsidiary of Biogen

Withdrawn

A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
Reata, a wholly owned subsidiary of Biogen

Terminated

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) (EAGLE)

Chronic Kidney Diseases | Autosomal Dominant Polycystic Kidney | Alport Syndrome

United States, France, Australia, Japan, Spain, Puerto Rico
Reata, a wholly owned subsidiary of Biogen

Completed

Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

Diabetic Nephropathy

United States
Reata, a wholly owned subsidiary of Biogen

Completed

Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic

United States
Reata, a wholly owned subsidiary of Biogen

Terminated

Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study

Diabetic Kidney Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of RTA 402 in Obese Adults

Obese Adult Male

Japan
NYU Langone Health
Reata Pharmaceuticals, Inc.

Completed

BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)

Covid19

United States
Reata, a wholly owned subsidiary of Biogen

Terminated

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER (RANGER)

Pulmonary Hypertension

United States, Spain, Australia, United Kingdom, Canada, Belgium, Argentina, Israel, Japan, Philippines, Germany, Mexico, Brazil, Czechia, Netherlands
Reata, a wholly owned subsidiary of Biogen

Completed

RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies

Advanced Solid Tumors | Lymphoid Malignancies

United States
Kyowa Kirin Co., Ltd.

Completed

A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy Adults

Healthy Subject

Japan
Reata, a wholly owned subsidiary of Biogen

Completed

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Diabetic Nephropathy | Type 2 Diabetes | Chronic Kidney Disease

United States
Reata, a wholly owned subsidiary of Biogen

Completed

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

Idiopathic Pulmonary Fibrosis | Pulmonary Arterial Hypertension | Pulmonary Hypertension | Interstitial Lung Disease | Sarcoidosis | Idiopathic Interstitial Pneumonia | Cryptogenic Organizing Pneumonia | Desquamative Interstitial Pneumonia | Respiratory Bronchiolitis Associated Interstitial Lung Disease and other conditions

United States, Germany
Reata, a wholly owned subsidiary of Biogen

Completed

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL (CARDINAL)

Alport Syndrome

United States, United Kingdom, Japan, Australia, France, Germany, Puerto Rico, Spain
Reata, a wholly owned subsidiary of Biogen

Terminated

Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

United States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines
Reata, a wholly owned subsidiary of Biogen

Terminated

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON)

Autosomal Dominant Polycystic Kidney | ADPKD

United States, Spain, United Kingdom, Australia, France, Japan, Germany, Belgium, Czechia, Italy
Reata, a wholly owned subsidiary of Biogen

Completed

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX (PHOENIX)

Focal Segmental Glomerulosclerosis | IgA Nephropathy | Autosomal Dominant Polycystic Kidney | CKD Associated With Type 1 Diabetes

United States
Pfizer

Terminated

Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Japan
Reata, a wholly owned subsidiary of Biogen

Completed

Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers

Healthy Volunteers

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN) (MERLIN)

Chronic Kidney Diseases

United States
Vanda Pharmaceuticals

Completed

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

Non-24-Hour-Sleep-Wake Disorder
Eisai Co., Ltd.

Completed

A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects

Healthy Subjects

Japan
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Ketones, SGLT2, HFrEF

Heart Failure With Reduced Ejection Fraction | Type2diabetes

United States
Reata, a wholly owned subsidiary of Biogen

Terminated

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer

United States
Peking Union Medical College Hospital

Not yet recruiting

Avatrombopag Usage in NSAA

Drug Effect | Aplastic Anemia

China
Pfizer

Completed

A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

Alopecia Areata

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Healthy

United States
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

Pharmacokinetics

Germany
Aelis Farma
European Commission

Recruiting

Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome (MDDS)

Down Syndrome

Spain
Aelis Farma
European Commission

Completed

AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects. (AEF0217-101)

Safety, Tolerability, Pharmacokinetics of AEF0217

Spain
Tourmaline Bio, Inc.

Recruiting

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 75 Years of Age With Thyroid Eye Disease (spiriTED)

Thyroid Eye Disease

United States, Jordan
Xenon Pharmaceuticals Inc.

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder (X-NOVA)

Major Depressive Disorder

United States
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

Dyslipidemias

Korea, Republic of
Oncology Institute of Southern Switzerland

Withdrawn

Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Prostate Cancer

Switzerland
Pfizer

Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Healthy | Diabetes Mellitus, Type 2 | Renal Impairment

United States
Instituto Nacional de Cancerologia de Mexico
Roche Pharma AG

Active, not recruiting

Tocilizumab Treatment in Patients With COVID-19

Sars-CoV2

Mexico
University of Utah

Completed

Remimazolam Sedation for Nerve Blocks (REMI-SEN)

Procedural Pain | Procedural Anxiety

United States
AstraZeneca

Completed

BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects

Gastric Ulcer | Duodenal Ulcer | Reflux Esophagitis | Anastomotic Ulcer | Etc.

Japan
University of Bologna
Ipsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaborators

Unknown

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

Non Small Cell Lung Cancer

Italy
Daiichi Sankyo, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Intra-Cellular Therapies, Inc.

Recruiting

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

Healthy Volunteers

United States
Addpharma Inc.

Completed

Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012

Hypertension | Hyperlipidemias

Korea, Republic of
Altavant Sciences GmbH
Parexel; Altavant Sciences, Inc.

Completed

Multiple-Ascending Dose in Japanese Patients Bridging Study

Healthy

United States

Search clinical trials for: Bardoxolone Methyl: 20 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations